Sanofi, Opella
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...
By deploying relatable imagery of princesses pooping, Dulcolax has set out to challenge societal norms that teach girls to be ...
Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...
Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...
When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the ...
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback